Generics of ‘Opsumit’ face tough competition in KOR
By Kim, Jin-Gu | translator Kim, Jung-Ju
24.02.29 12:08:53
가나다라
0
Samjin Pharm has launched Masiten after winning a patent challenge, and the priority of sale is set to expire on the first of next month
Daewoong’s ‘Macimit’ will enter the 15 billion won market, despite generics only having a 0.5% market share
▲The product photos of Opsumit (left) and Masiten (right).
In the market for the treatment of pulmonary arterial hypertension (PAH) with the active ingredient macitentan, the period of priority of sale given to the first generic drugs is set to expire on the first of next month. While Janssen’s ‘Opsumit’ competes with Samjin Pharm’s ‘Masiten’ in the market, Daewoong Pharmaceutical’s newly launched ‘Macimit’ is expected to join the competition.
As the generic’s market share is insignificant at below 1%, Daewoong’s introduction into the market draws the pharmaceutical industry’s attention related to potential market expansion in the treatment of pulmonary arterial hypertension (PAH) with the active ingredient macitentan.
Th
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)